Adverum Biotechnlgs (ADVM) |
|
13.92 1.75 (14.38%)
|
01-20 22:59 |
|
Open: |
13.26 |
Pre. Close: |
12.17 |
|
High:
|
14.79 |
Low:
|
13.24 |
|
Volume:
|
2,466,851 |
Market Cap:
|
1,357M |
|
|
|
|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
14.809 - 14.869 |
14.869 - 14.926 |
|
Low:
|
13.104 - 13.164 |
13.164 - 13.222 |
|
Close:
|
13.819 - 13.918 |
13.918 - 14.012 |
|
Technical analysis |
as of: 2021-01-20 4:44:04 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 17.27 One year: 20.18 |
| Support: |
Support1: 12.17 Support2: 10.55 |
| Resistance: |
Resistance1: 14.79 Resistance2: 17.27 |
| Pivot: |
11.87 |
| Moving Average: |
MA(5): 12.16 MA(20): 12.02
MA(100): 12.17 MA(250): 14.25 |
| MACD: |
MACD(12,26): -0.08 Signal(9): -0.25 |
| Stochastic oscillator: |
%K(14,3): 64.26 %D(3): 54.27 |
| RSI: |
RSI(14): 61.68 |
| 52-week: |
High: 26.98 Low: 7.36 Change(%): 19.6 |
| Average Vol(K): |
3-Month: 101923 10-Days: 102824 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ADVM has closed above the upper band by 29.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 14 Dec 2020
Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors - GlobeNewswire
Mon, 23 Nov 2020
Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference - GlobeNewswire
Sat, 14 Nov 2020
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD - GlobeNewswire
Thu, 05 Nov 2020
Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results - GlobeNewswire
Tue, 20 Oct 2020
Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual - GlobeNewswire
Tue, 18 Aug 2020
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
97 |
| Shares Float (M) |
67 |
|
% Held by Insiders
|
0.75 |
|
% Held by Institutions
|
96.25 |
|
Shares Short (K)
|
11,810 |
|
Shares Short P. Month (K)
|
13,020 |
Stock Financials |
|
EPS
|
-1.280 |
|
EPS Est This Year
|
-1.260 |
|
EPS Est Next Year
|
-1.310 |
|
Book Value (p.s.)
|
4.770 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-17.7 |
|
Return on Equity (ttm)
|
-31.4 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-0.412 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.003 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-72 |
|
Levered Free Cash Flow (M)
|
-63 |
Stock Valuations |
|
PE Ratio
|
-10.88 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.92 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-18.87 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
